Clinical Trial Update: This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO) [Phase 2]

View source ↗

Summary

Phase II study evaluating AZD6738 in combination with durvalumab in gastric adenocarcinoma and malignant melanoma (Cohort A: gastric cancer after secondary chem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Malignant Melanoma

Drugs mentioned

• AZD6738 (ceralasertib)
• Durvalumab (durvalumab)

Snippet

Sponsor: Samsung Medical Center | Conditions: Gastric Adenocarcinoma, Malignant Melanoma | Phase 2 | Status: UNKNOWN